The prognostic role of pretreatment C-reactive protein (CRP) has been reported for head and neck cancer. However, little is known about the relationship between the changes in CRP levels during treatment and prognosis. This study aimed to investigate the correlation between CRP elevation during concurrent chemoradiotherapy (CCRT) and survival outcomes.
The medical records of patients with oropharyngeal, hypopharyngeal, and laryngeal cancer treated with CCRT at the University of Tsukuba Hospital and National Hospital Organization Mito Medical Center from April 2014 to December 2019 were retrospectively reviewed. Patients were divided into normal (<0.3 mg/dl) and elevated (≥0.3 mg/dl) CRP groups according to the CRP level after the first cycle of cisplatin. The primary endpoint was progression-free survival (PFS).
A total of 74 patients were enrolled, of whom 36 (49%) showed elevated CRP levels after the first cycle of cisplatin. The 3-year PFS was 83.3% and 61.0% in the normal and elevated CRP groups, respectively, showing significant differences between the two groups.
Elevated CRP levels after the first cycle of cisplatin is an objective predictive marker for survival in patient with head and neck squamous cell carcinoma treated with CCRT.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Auris Nasus Larynx
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Head and neck squamous cell carcinoma.Nat Rev Dis Primers. 2020; 6: 92
- An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.J Clin Oncol. 2003; 21: 92-98
- C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review.PLoS One. 2015; 10e0143080
- The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: a meta-analysis.Cancer Med. 2020; 9: 9541-9553
- AJCC cancer staging manual.8th ed. Springer, New York2017: 58-60
- The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy.Sci Rep. 2017; 7: 17805
- The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.Oncotarget. 2018; 9: 37008-37016
- Investigation of the freely available easy-to-use software “EZR” for medical statistics.Bone Marrow Transplant. 2013; 48: 452-458
- Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer.Head Neck. 2015; 37: 1745-1749
- Role of interleukin-6 in cancer progression and therapeutic resistance.Tumour Biol. 2016; 37: 11553-11572
- Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels.Oncotarget. 2017; 8: 100339-100352
- Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.Eur J Nucl Med Mol Imaging. 2022; 49: 1650-1660
- Systemic inflammatory reaction in patients with head and neck cancer-an explorative study.Front Oncol. 2019; 9: 1177
- Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters.Brain Behav Immun. 2018; 70: 61-75
- Radiotherapy and radiochemotherapy increase serum levels of pro-inflammatory interleukin-6 and C-reactive protein in patients with head and neck cancers.Transl Cancer Res. 2018; 7: 41-47
- Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells.Am J Respir Cell Mol Biol. 1998; 19: 653-661
- PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.J Exp Med. 2014; 211: 781-790
- Tumor immune microenvironment in head and neck cancers.Mol Carcinog. 2020; 59: 766-774
- Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas.J Natl Cancer Inst. 2018; 110: 1386-1392
- Cigarette smoke induces metabolic reprogramming of the tumor stroma in head and neck squamous cell carcinoma.Mol Cancer Res. 2019; 17: 1893-1909
- Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial.J Clin Oncol. 2022; 40: 1980-1990
- Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review.Head Neck. 2016; 38: E2151-E2158
- Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects?.J Clin Oncol. 2004; 22: 4657-4659
- Acute-phase response reactants as objective biomarkers of radiation-induced mucositis in head and neck cancer.Head Neck. 2012; 34: 985-993
- C-reactive protein levels and radiation-induced mucositis in patients with head-and-neck cancer.Int J Radiat Oncol Biol Phys. 2009; 75: 393-398
Published online: January 03, 2023
Accepted: December 26, 2022
Received: August 23, 2022
Publication stageIn Press Corrected Proof
Prior presentation: None
© 2023 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V.